Tech Company Inital Public Offerings
TScan Therapeutics IPO
TScan Therapeutics, based in Waltham, debuted as a public company on 7/16/2021.
Transaction Overview
Company Name
Announced On
7/16/2021
Transaction Type
IPO
Amount
$94,500,000
Proceeds Purpose
Use of proceeds for the TScan Therapeutics IPO are outlined in the company's S1 filing.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
830 Winter St.
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Website
Email Address
Overview
TScan Therapeutics is an experienced group of scientists, development specialists, and other leaders driving a cutting edge platform. TScan Therapeutics is an owner and operator of a biotechnology company intended to develop immunotherapy treatments for cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Southwell
Chief Scientific Officer
Gavin MacBeath
VP - Bus. Development
Henry Rath
VP - Finance
Shane Maltbie
VP - Human Resources
Ann Hargraves
Browse more venture capital transactions:
Prev: 7/16/2021: Imperative Care venture capital transaction
Next: 7/16/2021: Stemson Therapeutics venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs